SUMMARY In a prospective study of 143 patients with systemic lupus erythematosus (SLE) the relation between clinical exacerbations, anti-dsDNA levels, and serum levels of complement components, Clq, C4, C3, C5, and C9 was investigated. In 33 out of these 143 patients a major clinical exacerbation of the disease developed. Evaluation of anti-dsDNA levels in relation to disease activity confirmed our earlier finding that anti-dsDNA levels rose before a major exacerbation and decreased after it. In the remaining 110 SLE patients a nearly constant anti-dsDNA level was seen, but none of these patients experienced a major exacerbation. In the 21 SLE patients who developed deterioration in renal function a decrease of C4 followed by decreases of Clq and C3 levels was seen first, starting about 25 to 20 weeks before the first signs of renal involvement. In the 12 SLE patients who developed an exacerbation without renal involvement an inconsistent profile of the complement components C4, Clq, and C3 was observed. C5 levels were hardly affected at l, while C9 levels were in general higher than normal during the exacerbation, irrespective of the type of exacerbation. These results show that, by following the complement and anti-dsDNA profiles, not only can exacerbations be predicted but also a pointer can be obtained about the pattern of disease well before the first clinical signs of an exacerbation appear.
Serum complement levels are often used as prognostic indicators and diagnostic aids in patients with systemic lupus erythematosus (SLE). Diminished serum complement activity (CH50 titre) has been claimed to accompany or precede the onset of nephritis. ' Exacerbations of nephritis have also been described without a fall in the serum complement level.2 Specifically, the presence of low levels of Clq or C4 has been claimed to be a sign of the presence of renal disease or the tendency to develop it.3 4 In later studies lower mean levels of Clq, C4, and C3, but not of C5 and C9, were observed in SLE patients with renal involvement.56 In two prospective follow up studies normalisation of serum CHs,, or Clq and C3 levels was associated with improvement in renal function.7 8 Up till now there have been no available serial data, gathered in Department of Internal Medicine of the Slotervaart Hospital (Amsterdam), the Department of Internal Medicine of the Free University Hospital (Amsterdam), and the Department of Rheumatic Diseases of the Dr Daniel den Hoed Hospital (Rotterdam). Venous blood was collected from 143 patients meeting the preliminary criteria for the diagnosis of SLE.9 Samples from all these patients were obtained at four to six week intervals. After coagulation and centrifugation the sera were stored at -20°C.
When the patients developed additional complaints or manifestations of their disease the frequency of clinical and serological investigations was increased, if possible, to one to three week intervals. Disease activity was recorded without knowledge of the serological parameters, and treatment of the patients was not influenced by serological data. Signs of disease activity, medication, indications for dosage alterations, and routine clinical laboratory results were recorded on standard clinical record sheets. Exacerbations were defined by the occurrence of major disease features.8 I( Minor symptoms were mainly restricted to the musculoskeletal system and the skin, which could be controlled by an increase in prednisolone dosage of 5-15 mg/day without the need for admission to hospital. Major features were characterised by at least one of the following: renal impairment, serositis, anaemia (Hb <7 g/dl (70 g/l) and/or leucopenia (white cell count <4x 109/l) and/or thrombocytopenia (platelet count <50x 109/l), neurological or psychiatric symptoms.
These features always led to hospitalisation, and the dosage of prednisolone was increased to more than 20 mg/day. Episodes in which the features were explained by causes other than SLE were excluded.
Patients with pre-existing renal involvement were considered to be inactive when no significant alterations took place in the creatinine values, proteinuria, and urine sediment. An C4, and C3 levels tended to become normal rapidly. 80 The increase seemed to occur faster than the decrease. Fig. 3 (Fig. 5 ). In the patients with decreasing Clq levels or C3 levels, or both, no clear relation was found between the course of these levels and the developing exacerbation. During a relatively long time period preceding the exacerbation steadily decreasingly Clq or C3 levels, or both, were found. Only the C4 levels showed the clear relation between fall and approaching exacerbation. In the C5 and C9 profiles (Fig. 6 ) no 'abnormalities' were detected: both complement components were always either within the normal range or increased.
ANTI-dsDNA PROFILES IN THE 33 PATIENTS WHO DEVELOPED AN EXACERBATION
In the 24 weeks preceding exacerbations a continuous increase in the anti-dsDNA was found for all patients with a doubling time (t2) of less than 10 weeks. In 28 patients the t2 was even shorter than six weeks. The actual exacerbations were characterised by rapidly decreasing levels of anti-dsDNA: 29 patients had a t½/2 shorter than three weeks; the other four patients showed a t/2 shorter than six weeks.
PREDICTIVE VALUE OF THE LEVELS OF COMPLEMENT COMPONENTS
Two patients in whom a deterioration of the renal function developed showed first a decrease in the C4 levels, followed later by falls in Clq, then C3 (see Fig. 1 ). In the non-renal patients, however, decreased complement levels were also seen. To evaluate which patients were prone to develop renal involvement at t=0 all data of the 33 exacerbations were taken together. Firstly, the separate complement components were considered in relation to the development of renal involvement. Secondly, to increase the specificity, combinations of the complement components were examined ( 5 Correlation between the profiles of complement components, anti-dsDNA, and course ofthe disease. Patient 2 was a 47 year old male, whose diagnosis ofSLE was made in 1974. At that time he was admitted to hospital with pleuritic pain. Serological examination showed anaemia and leucocytopenia. Periods ofpolyarthritis followed. On 4 July 1982 (month 6) he entered hospital with fever (40 5°C); pleuropericarditis was then diagnosed. The anti-dsDNA on 5 July was 2960 units/ml, on 8 July 1720 unitslml, and on 11 July 216 unitslml. Prednisolone therapy (100 mglday) was started on 8 July. On Decreased C5 or C9 levels were detected in hardly any of these patients.
this study, increasing levels of anti-dsDNA combined with decreasing complement levels were never observed.
Discussion
The complement system is thought to be involved in the immune complex mediated lesions of SLE with deposition of complement in renal and other lesions. The level of serum complement, therefore, may represent an indicator of disease activity. In our retrospective study8 evidence of renal involvement was observed when the decrease of high anti-dsDNA was accompanied by very low (-40%) serum levels of the complement factors Clq and C3. In that study two out of 43 patients were observed with low Clq and normal C3, but neither of these two patients showed symptoms of 00 C9
_. C5 24  24  63  7  100  50  83  0  0  0  0  20  29  80  23  75  62  80  6  100  6  100  16  40  75  40  88  60  90  15  100  15  100  12  37  77  41  90  66  75  13  100  13  100  8  50  83  50  90  70  75  29  100  29  100  4  53  80  59  87  74  70  39  100  32  100  0  66  86  69  82  75  72  54  94  54 Levels of C5 in patients with renal involvement tended to be lower than in patients without renal involvement. In this prospective study we confirmed in a larger group of patients our earlier findings of the relation between the course of the disease and the anti-dsDNA profiles. All observed periods of major flares were heralded by a period of increasing levels of anti-dsDNA. Then, once the exacerbation started, the anti-dsDNA levels decreased rapidly. Thirty three such exacerbations were observed in 143 patients. In the remaining 110 patients (none of whom developed a major exacerbation) antidsDNA levels remained constant during the time they were studied. This study was specifically focused on those patients with changing antidsDNA levels, and it became clear that changes in anti-dsDNA content associated with the three different complement components (Clq, C4, and C3) had the most prognostic significance, as follows: (a) The 21 patients who were about to develop renal involvement were characterised by an initial decrease of C4, followed by Clq and C3. During the phase of exacerbation Clq and C3 increased first, followed later by C4 (Fig. 2) 
